Current clinical trials in castrate-resistant prostate cancer
DP Petrylak - Current Urology Reports, 2011 - Springer
Seven years passed since docetaxel/prednisone demonstrated and overall survival benefit,
leading to its approval by the FDA for metastatic castration resistant prostate cancer. In 2010 …
leading to its approval by the FDA for metastatic castration resistant prostate cancer. In 2010 …
Current Clinical Trials in Castrate-Resistant Prostate Cancer
DP Petrylak - Current Urology Reports, 2011 - infona.pl
Seven years passed since docetaxel/prednisone demonstrated and overall survival benefit,
leading to its approval by the FDA for metastatic castration resistant prostate cancer. In 2010 …
leading to its approval by the FDA for metastatic castration resistant prostate cancer. In 2010 …
Current clinical trials in castrate-resistant prostate cancer.
DP Petrylak - Current Urology Reports, 2011 - europepmc.org
Seven years passed since docetaxel/prednisone demonstrated and overall survival benefit,
leading to its approval by the FDA for metastatic castration resistant prostate cancer. In 2010 …
leading to its approval by the FDA for metastatic castration resistant prostate cancer. In 2010 …
[引用][C] Current Clinical Trials in Castrate-Resistant Prostate Cancer
DP Petrylak - Current Urology Reports, 2011 - cir.nii.ac.jp
Current clinical trials in castrate-resistant prostate cancer
DP Petrylak - Current urology reports, 2011 - pubmed.ncbi.nlm.nih.gov
Seven years passed since docetaxel/prednisone demonstrated and overall survival benefit,
leading to its approval by the FDA for metastatic castration resistant prostate cancer. In 2010 …
leading to its approval by the FDA for metastatic castration resistant prostate cancer. In 2010 …